Detaching Vero, MDCK and HEK 293 at Scale: An Animal-Free Enzyme for Vaccine and Viral-Vector Production

Animal-free trypsin for vaccine production is no longer a niche preference — it is increasingly the default expectation of quality units reviewing an adherent cell process. This application note looks at what a recombinant, animal-origin-free trypsin-like enzyme does when it is used to release the three workhorse adherent lines of viral manufacturing — Vero, MDCK and HEK 293 — what the manufacturer has actually measured, and, just as importantly, what has not been measured yet.

Why animal-origin trypsin is a documentation problem, not just a preference

Porcine pancreatic trypsin has been the standard dissociation reagent for adherent culture for decades. Its weakness is not enzymatic — it is provenance. A US FDA study screening vaccine-relevant cell substrates for porcine circovirus put the issue plainly: “animal-derived raw materials, such as cells, trypsin, and serum, can be a major source of introducing virus contamination in biological products” (Ma et al., Vaccine 2011).

That is not a theoretical concern. In 2010, porcine circovirus type 1 DNA was detected in a licensed live-attenuated human rotavirus vaccine, prompting a full manufacturer investigation and a temporary regulatory suspension of use in the United States (Dubin et al., Hum Vaccin Immunother 2013). Independent screening by NIBSC subsequently found PCV1 DNA in live poliovirus seeds from one manufacturer, although the finished inactivated product tested negative (Gilliland et al., Biologicals 2012). The downstream commercial effect was measurable: one analysis recorded a 93% drop in doses of the affected vaccine in the month after the suspension notice (Dore et al., Pharmacoepidemiol Drug Saf 2012).

Removing animal-derived material from the process does not eliminate adventitious-agent risk, but it removes one well-documented route in. That is the argument for a recombinant enzyme, and it is an argument about traceability and viral safety — not about detachment speed.

What CellTrypase is, and how it is specified

CellTrypase (c-LEcta GmbH, a Kerry company) is a recombinant trypsin-like serine protease. The gene originates from the fungus Fusarium oxysporum and is expressed in a Bacillus sp. host at GMO safety level S1. The mature enzyme is approximately 22 kDa and cleaves on the carboxyl side of lysine and arginine residues — the same specificity that makes mammalian trypsin useful for releasing adherent cells.

The specification a process development scientist actually needs:

Two handling points matter for scale-up. First, no trypsin inhibitor is required — activity is quenched by dilution in buffer or medium, which removes a reagent, a hold step and an inhibitor-carryover question from the process. Second, the recommended dose is approximately 1 mL per 25 cm² of growth surface, with the enzyme pre-warmed to room temperature or 37 °C before addition.

Manufacturer release data for Vero, MDCK and HEK 293 — including the MDCK outlier

c-LEcta reports application data for four production lines. These are the only cell types for which performance figures exist, and they are reproduced here in full, including the result that is least flattering.

Source: c-LEcta PIS CellTrypase v2.0. CHO-K1 is included for completeness.

Read the MDCK row carefully. At 23 minutes 32 seconds, MDCK release took roughly ten times longer than HEK 293 or CHO-K1 under the manufacturer's conditions. Viability and yield held up — 99% and 102% — so the cells came off intact, but they came off slowly. If you run MDCK, this is a scheduling fact you need before you plan a harvest, not after. Practical consequences:

• A 20-plus minute enzyme exposure changes the hold time of every vessel in a parallel harvest. Budget for it in your batch record.
• Longer exposure at 37 °C is worth evaluating against room-temperature incubation for your own line, since MDCK sublines differ substantially in adhesion behaviour.
• The 10x concentrate exists and is an obvious variable to test for slow-releasing lines — but c-LEcta publishes no MDCK data at 10x, so treat that as an experiment to run, not a result to assume.

One further caution on interpreting the table: yield is reported relative to a reference condition, which is why values sit slightly above 100%. Confirm the reference definition in the PIS before you carry these numbers into a comparability protocol.

Trypsin has two jobs in an influenza process — this enzyme is documented for one

This distinction is missed often enough to be worth stating directly. In MDCK-based influenza manufacturing, trypsin appears at two separate points:

1. Cell dissociation — releasing the monolayer for passaging or harvest.
2. Haemagglutinin activation — exogenous protease supplied during infection to cleave HA0 into HA1/HA2 and permit multi-cycle replication.

The second role is a genuine process parameter with measurable effects on titre. Trypsin added during infection has been shown to interfere with the antiviral host response in MDCK cells, contributing to yield beyond simple HA cleavage (Seitz et al., Appl Microbiol Biotechnol 2011), and protease source and concentration have been optimised as independent variables for H1N1 replication in MDCK (Iskandar et al., J Virol Methods 2017).

CellTrypase is characterised and supplied as a dissociation reagent. c-LEcta publishes no data on HA activation, infection-phase protease performance or virus titre. Do not assume that replacing your dissociation enzyme also replaces your infection-phase protease — those are two qualification exercises, and only the first is supported by data today.

Scaling the dose: volume and cost arithmetic for flasks, stacks and microcarriers

At the recommended ~1 mL per 25 cm², enzyme volume scales linearly with growth surface:

Using eBioHippo list prices at the time of writing, and diluting the 10x concentrate 1:10 to make working solution, cost per millilitre of 1x working solution works out at roughly $0.09 (R&D grade from 10x, 500 mL) to $0.29 (GMP grade, ready-to-use 1x, 500 mL). For a single ~6,300 cm² vessel that is approximately $23 to $74 of enzyme per harvest. This is simple arithmetic on published list prices, excluding shipping and duties — treat it as an order-of-magnitude planning figure, not a quotation. Two honest qualifications: diluting a 10x concentrate introduces an additional open manipulation and a diluent that you must qualify, which may be unattractive in a GMP suite; and pack size, not unit price, usually drives real cost at scale.

For microcarrier and fixed-bed processes, be aware that the published data does not apply. Vero and HEK 293T are routinely expanded on microcarriers in single-use bioreactors (Yang et al., AMB Express 2019), and Vero processes remain adherent even at production scale, whether on microcarriers or fixed-bed (Kiesslich et al., J Biotechnol 2020). Bead-to-bead transfer and microcarrier harvest are mechanically and enzymatically different from releasing a flask monolayer, and c-LEcta reports no microcarrier data. If your process runs on beads, that is a study you need to run.

What the data does not cover

Being specific about gaps is more useful than being vague about strengths. As of PIS v2.0, c-LEcta reports no performance data for:

• Replating efficiency, proliferation rate or long-term culture performance after dissociation, in any cell type.
• Any cell type other than CHO-K1, HEK 293, MDCK and Vero. Induced pluripotent stem cells, organoids, primary cells, neurons, mesenchymal stromal cells, T cells, cardiomyocytes and RPE are listed by the manufacturer as intended applications, but no viability, yield, recovery or marker-retention figures are published for them.
• Microcarrier, fixed-bed or bead-to-bead applications.
• Infection-phase protease performance or virus titre.
• Long-term stability beyond the confirmed 15 months at 2–8 °C; c-LEcta states this study is ongoing. Brief warm excursions during shipping are reported not to affect activity.

Where the numbers do not exist, the sensible answer is a bench comparison rather than a claim. c-LEcta and eBioHippo offer a free 100 mL sample for exactly this purpose. A defensible mini-study is small: run your current reagent and CellTrypase side by side on your own line, at your own confluence and vessel format, and record release time, trypan-blue or automated viability, recovered cell number, and — because it is the endpoint that actually matters and the one with no vendor data behind it — attachment and growth over the next two passages.

If you are considering a switch

Dosing translates one-to-one: the same volume per unit growth area you use today, pre-warmed. That is dosing guidance only — verify detachment time and viability in your own cell model before switching, and treat the switch as a change to your process that your own change-control system governs. No supplier can waive that on your behalf.

Useful next steps: the step-by-step CellTrypase dissociation protocol covers handling and quenching in detail; the CellTrypase specification comparison sets out the full attribute list. Related adherent production lines are listed under cell lines, and process-scale quantities can be scoped through a quote request.

References

1. Ma H, et al. Investigations of porcine circovirus type 1 (PCV1) in vaccine-related and other cell lines. Vaccine 2011;29(46):8429–37. doi:10.1016/j.vaccine.2011.07.123
2. Dubin G, et al. Investigation of a regulatory agency enquiry into potential porcine circovirus type 1 contamination of the human rotavirus vaccine, Rotarix. Hum Vaccin Immunother 2013;9(11):2398–408. doi:10.4161/hv.25973
3. Gilliland SM, et al. Investigation of porcine circovirus contamination in human vaccines. Biologicals 2012;40(4):270–7. doi:10.1016/j.biologicals.2012.02.002
4. Dore DD, et al. Vaccine discontinuation and switching following regulatory interventions in response to rotavirus vaccine contamination with porcine circovirus DNA fragments. Pharmacoepidemiol Drug Saf 2012;21(4):415–9. doi:10.1002/pds.3217
5. Seitz C, et al. Trypsin promotes efficient influenza vaccine production in MDCK cells by interfering with the antiviral host response. Appl Microbiol Biotechnol 2011. doi:10.1007/s00253-011-3569-8
6. Iskandar A, et al. Optimization of trypsins for influenza A/H1N1 virus replication in MDCK SI-6 cells. J Virol Methods 2017. doi:10.1016/j.jviromet.2017.11.006
7. Yang Z, et al. Large-scale microcarrier culture of HEK293T cells and Vero cells in single-use bioreactors. AMB Express 2019. doi:10.1186/s13568-019-0794-5
8. Kiesslich S, et al. Serum-free production of rVSV-ZEBOV in Vero cells: microcarrier bioreactor versus scale-X hydro fixed-bed. J Biotechnol 2020. doi:10.1016/j.jbiotec.2020.01.015
9. Genzel Y, et al. MDCK and Vero cells for influenza virus vaccine production: a one-to-one comparison up to lab-scale bioreactor cultivation. Appl Microbiol Biotechnol 2010. doi:10.1007/s00253-010-2742-9
10. c-LEcta GmbH. Product Information Sheet, CellTrypase v2.0.

Figures 1–3 are illustrative summaries of manufacturer specification data, published list prices and the qualification steps described in this article. They are visualisations prepared by eBioHippo, not experimental data generated by eBioHippo. Literature identified via PubMed. TrypLE™ is a trademark of Thermo Fisher Scientific Inc. It is referenced here only to identify a widely used class of recombinant dissociation reagent; no affiliation with, sponsorship by or endorsement from Thermo Fisher Scientific is implied. R&D-grade CellTrypase is supplied For Research Use Only (RUO) and is not for use in diagnostic or therapeutic procedures. GMP-grade material is supplied as a processing aid for biopharmaceutical manufacturing and is not for direct administration to humans or animals. Prices cited are eBioHippo list prices at the time of writing and are subject to change.